

Erenumab for preventing migraine

Information for the public

Published: 10 March 2021

www.nice.org.uk

Erenumab (Aimovig) is available on the NHS as a possible treatment for preventing migraine in adults who:

- have 4 or more migraine days a month
- have tried at least 3 other medicines and they have not worked, or are not tolerated or are unsuitable because of safety concerns
- take the 140 mg dose of erenumab.

You should only continue taking erenumab after 12 weeks of treatment if:

- episodic migraine (less than 15 headache days a month) reduces by at least 50% (for example, from 10 days to 5 days a month)
- chronic migraine (15 headache days a month or more and at least 8 of those have been migraines) reduces by at least 30% (for example, from 20 days to 14 days a month).

If you are not eligible for erenumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Migraine Trust](#), 0203 9510 150
- [OUCH \(UK\)](#), 01646 651 979

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3977-0